Compare Boston Scientific Corporation (BSX) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs ProShares Ultra QQQ ETF — how do they compare? Boston Scientific Corporation trades at $42.71 (market cap $66.37B), while ProShares Ultra QQQ ETF trades at $92.98. The key difference: ProShares Ultra QQQ ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | QLD | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $108.14 | $100.53 |
52-Week Low | $42.63 | $57.16 |
Enterprise Value | $75.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
QLD, the ProShares Ultra QQQ ETF, trades at $90.13, down 3.81% over 24 hours, reflecting a bearish technical signal with key support at $87. As a 2x daily leveraged ETF tracking the Nasdaq-100, it offers amplified exposure to large-cap tech stocks but carries inherent volatility risks. Recent news highlights its long-term performance, with over 10,000% total return since inception, though comparisons with 3x leveraged alternatives underscore drawdown vulnerabilities.
The outlook for QLD hinges on Nasdaq-100 momentum, with tech earnings and AI optimism as potential catalysts. However, leveraged decay and market volatility pose significant risks, making it suitable only for tactical, risk-tolerant investors. Current neutral oscillators suggest near-term consolidation, but bearish moving averages indicate downward pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
